Company
Every investor coverage indicates participated in a round Immatics N.V. raised.
Companies Immatics N.V. acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Thomas Ulmer | Chief Financial Officer (former) | Brandon BioCatalyst portfolio |
Stories naming Immatics N.V.. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Biotech firm Aravax has added Thomas Ulmer, previously CFO at Immatics and Allergopharma with Merck roles, to its board as its peanut allergy treatment advances after positive phase 1 safety results.